August 9, 2023 06:11 AM EDTUpdated 08:27 AM
R&D

No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Reynald Castañeda

Deputy Editor

No­var­tis re­vealed pos­i­tive news from two Phase III tri­als that are study­ing its oral BTK in­hibitor remi­bru­ti­nib in chron­ic spon­ta­neous ur­ticaria, set­ting up po­ten­tial reg­u­la­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times